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Abstract
Background: Studies have suggested an increasing practice of concurrent herb-drug consumption. One of the major clinical risks of such
concomitant herb-drug use is pharmacokinetic herb-drug interaction (HDI). This is brought about by the ability of phytochemicals to inhibit or
induce the activity of metabolic enzymes. The aim of this study was to investigate the potential of the crude aqueous extracts of three popular
medicinal herbs used in South Africa to inhibit major cytochrome P450 (CYP) enzymes.
Materials and Methods: The extracts of Bowiea volubilis, Spirostachys africana and Tulbaghia violacea were incubated with human liver
microsomes (HLM) to monitor the phenacetin O-deethylation, diclofenac 4’-hydroxylation, S-mephenytoin 4’-hydroxylation and testosterone 6β-
hydroxylation as respective probe reactions for CYP1A2, CYP2C9, CYP2C19 and CYP3A4. The inhibitory activity, where observed, was
profiled against the extract concentration.
Results: Extracts of Bowiea volubilis inhibited the metabolic activity of CYP1A2 and CYP3A4 with IC50 values of 92.3 ± 5.5 g/mL and 8.1 ±
0.6 g/mL respectively. Similar observation with Spirostachys africana showed inhibitory activity against CYP1A2 and CYP3A4 with respective
IC50 values of 14.3 ± 0.6 g/mL and 47.4 ± 2.4 g/mL. Tulbaghia violacea demonstrated relatively weak inhibitory activity against CYP1A2
(767.4 ± 10.8 g/mL) and CYP2C9 (921 ± 15.3 g/mL).
Conclusion: The results suggest the potential for HDI between the herbs and the substrates of the affected enzymes, if sufficient in vivo
concentration is attained.
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Introduction
The concomitant use of medicinal herbs and orthodox medicine has been well reported and documented (Canter and Ernst, 2004;
Delgoda et al., 2010). This is despite the lack of sufficient scientific information on the efficacy and toxicology on most of the herbal products.
One of the clinically important consequences of the concomitant use of herbs and prescription drugs is the risk of pharmacokinetic herb-drug
interaction (HDI). The ability of phytochemicals to inhibit or induce drug metabolizing enzymes especially the cytochrome P450 (CYP) enzyme
family is known to be the key mechanism for pharmacokinetic HDI (Fasinu et al., 2012). While a number of plant products such as garlic and St
John’s wort, that are popular in developed countries have been well studied for their effects on CYP and transport proteins, there is dearth of
information on the potential of most African herbal products for HDI (Fugh-Berman, 200; Nowack, 2008). In our earlier studies, extracts of
Sutherlandia frutescens and Hypoxis hemerocallidea showed strong inhibitory activity against CYP and transport proteins (Fasinu et al., 2013a;
2013b). In this current study, three important herbs – Bowiea volubilis, Spirostachys africana and Tulbaghia violaceae - widely consumed in
South Africa for medicinal purposes were identified and investigated for potential HDI.
Bowiea volubilis is known as ‘climbing onion’, and locally as ugibisisila (isiZulu), umgaqana (IsiXhosa) or Knolklimop (Afrikaans). It
is widely sought after by indigenous South Africans for numerous medical conditions including dermatological disorders, sore eyes, urinary
complications, infertility, facilitation and induction of abortion (Steenkamp, 2003). Some studies have claimed that its extracts demonstrated
moderate in vitro antibacterial and antifungal activity (Buwa et al., 2006; Van Vuuren and Naidoo, 2010).
Spirostachys africana is widely distributed in the vegetations of Southern Africa. A number of phytochemicals including stachenone,
diosphenol and diterpenoid derivatives have been isolated and identified as active constituents (Duri et al., 1992). The latex is traditionally used in
South Africa and Zimbabwe as purgative, to stimulate emesis, and manage infective diarrhoea and dysentery (Gelfand et al., 1995); as anti-
malarial in Tanzania and Mozambique and as topical anti-infective in South Africa (Munkombwe et al., 1997; 1998). It is used in South Africa,
especially among the IsiXhosa-speaking people for the topical treatment of infantile cradle cap known locally as ishimca (Beach et al., 2010). In
vitro studies have shown anti-microbial activity of isolated compounds against Escherichia coli, Salmonella typhi, Shigella dysentery,
Staphylococcus aureus and Vibrio cholera (Mathabe et al., 2006; 2008). A clinical study of the anti-malarial preparation from S. africana
conducted in Mozambique reported significant reduction in parasitaemia (Jurg et al., 1991).
Tulbaghia violacea is traditionally used for the treatment of respiratory disorders including tuberculosis, asthma; gastrointestinal
ailments, oesophageal cancer, fungal infection, fever and colds (Van den Heever et al., 2008). The close association between HIV/AIDS and
tuberculosis has made it popular among people living with HIV/AIDS in South Africa. It contains a C–S lyase, cysteine and tetrathiaoctane
derivatives (Kubeca et al., 2002). It inhibits angiotensin converting enzyme (ACE) supporting its use in hypertension (Duncan et al., 1999). Its
extracts inhibited the growth of cancer cells and induced apoptosis in an in vitro study (Bungu et al., 2006). Other studies have suggested its
anthelmintic and antifungal activity especially against Candida albicans, a common cause of infection in HIV/AIDS patients (McGaw et al.,
2000; Motsei et al., 2003; Thamburan et al., 2006).
Concomitant use of herbs and orthodox medicine has been reported to be common among South African patients (Bepe et al., 2011).
The popularity of Bowiea volubilis, spirostachys Africana and Tulbaghia violacea makes them likely candidates for such concurrent use. While a
number of CYP isozymes participate in drug metabolism, CYP1A2, CYP2C9, 2C19 and 3A4 are responsible for the CYP-dependent metabolism
of over 90% of marketed drugs. CYP1A2 has been shown to be exclusively expressed in the liver constituting about 13-15% of the total hepatic
CYP content (Shimada et al., 1994; Martignoni et al., 2006). It is the primary enzyme responsible for the phase I metabolism of a number of
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drugs including tacrine, theophylline, and clozapine. CYP1A2-catalyzed O-deethylation to phenacetion to form the active acetaminophen is the
most widely used in vitro and in vivo probe reaction for evaluating the activity of CYP1A2 (Faber et al., 2005).
CYP2C (mainly 9 and 19) accounts for about 20% of the total human hepatic CYP (Gerbal-Chaloin et al., 2001; Martignoni et al.,
2006), and the second most abundant CYP after 3A. CYP2C9 is the most abundantly expressed CYP2C isozyme (Rettie and Jones, 2005). One of
the most well established in vitro CYP2C9-specific probe substrate is diclofenac (Konecný et al., 2007; Tai et al., 2008) while S-mephenytoin has
been established, and used extensively as an in vitro probe substrate for CYP2C19 metabolic activity.
CYP3A4/5 is expressed in the liver and in extra-hepatic tissues and accounts for about 80% of intestinal CYP where it is responsible for
pre-systemic drug metabolism (Paine et al., 2006). The CYP3A4 enzyme is the most important drug-metabolizing CYP accounting for about
40% of the total hepatic CYP (although the levels may vary 40-fold among individuals), and 50% of all CYP-mediated drug metabolism (Rendic,
2002; Ferguson and Tyndale, 2011; Singh et al., 2011). The inhibition of both intestinal and liver CYP3A4 has been shown to contribute to drug-
drug interaction (Galetin et al., 2007). Testosterone hydroxylation is one of the very CYP3A4-specific reactions and is thus used as CYP3A4
probe in an enzyme mix.
The aim of the current study was to investigate the inhibitory effects of the crude extracts of Bowiea volubilis, Spirostachys africana
and Tulbaghia violacea on CYP1A2, CYP2C9, CYP2C19 and CYP3A4 using pooled human liver microsomes (HLM) expressing these CYP
isozymes. The specimens were to be sourced from traditional health practitioners (THP) and prepared in reflection of traditional use.
Materials and Methods
Plant materials
Fresh samples of the specimens (bulbs of Bowiea volubilis and Tulbaghia violacea; and stem bark of Spirostachys africana) were
obtained from two South African THPs after a mutually acceptable material transfer agreement (MTA) was signed in accordance with the
University’s and the country’s regulations on indigenous knowledge. The samples together with their representative flowering portions were
identified by Kwaleta Sibuyile and Viola Kalitz of the Stellenbosch University botanical garden where prepared voucher specimens were
deposited with voucher identification numbers PSF#12, PSF#13 and PSF#14 respectively. Information on the mode of use, dosage and specific
indications were obtained and documented through semi-structured interview. Ethical approval was obtained from the University of Stellenbosch
Health Research Ethics Committee.
Chemical compounds
The chemical compounds employed in the study were obtained as indicated: 4’-hydroxymephenytoin, 6β-hydroxytestosterone, 4’ 
hydroxydiclofenac, diclofenac acetaminophen, NADPH and testosterone from Sigma-Aldrich (Pty) Ltd (St. Louis, USA); dimethylsulfoxide
(DMSO), phenacetin, magnesium chloride hexahydrate, potassium dihydrogen phosphate (KH2PO4), di-potassium hydrogen phosphate
(K2HPO4), acetonitrile, formic acid and methanol from Merck Chemicals (Pty) Ltd (Darmstadt, Germany). All other chemicals and reagents used
were of analytical grade.
Assay enzymes
Pooled mixed gender HLM prepared from 50 individual donors with total CYP and cytochrome b5 content of 290 pmol/mg protein and
790 pmol/mg proteins respectively was obtained from Gentest BD Biosciences (Woburn, MA, USA), stored at -80ºC and thawed according to
supplier instructions before use. The catalytic activities of the constituent CYP enzymes were provided by the manufacturer.
Extraction of Plant Material
The medicinal samples were air-dried and ground. This was followed by aqueous extraction (50mg/mL) in a round bottom flask. After
the initial stirring for 2 hours, the mixture was allowed to extract for 24 hours, decanted, and centrifuged (20,000 rpm, 5min). The supernatant
was filtered (0.45µL; Whatman International LTD, Maidstone, England) and freeze-dried. The dried extracts were stored at -20ºC in air-tight
containers, and were reconstituted in water just before use.
Incubation in HLM
Thawed HLM were diluted with potassium phosphate buffer (50mM; pH = 7.4) and incubated in 96-well plate format. Graded
concentrations of the herbal extracts were prepared in methanol such that the addition of 1µL to 200µL incubation mixture yielded a final extract
concentration of 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50 and 100µg/mL respectively. Appropriate CYP substrate (table 1) was added and the
mixture pre-incubated at 37°C for 10 minutes using an IS89 96-well plate incubator (Wesbart, Leimuiden, The Netherlands). Metabolic reactions
were initiated by adding NADPH (1mM) and magnesium chloride (5mM) solution, and terminated after 20 minutes through the addition of
formic acid (10 µL; 50%). All incubations were performed in duplicate. Control incubations contained CYP-specific inhibitor, and incubations
without inhibitors (Table 1). The final methanol concentration in the incubations was 0.5% (v/v). Probe substrate concentrations used were less or
equal to published Km values. Other conditions for microsomal incubation are summarized in Table 1.
Quantitative analysis of metabolites
LC-MS methods were developed to analyze CYP substrates/metabolites. Total separation and elution of the analytes were achieved
within 10 minutes run time. Reproducibility of the quantitative analysis was assessed through repeat injections at different times. Intra-day and
inter-day variations were insignificant (less than 5%). LC/MS conditions are summarized in Table 2. Solid-phase extraction using OASIS HLB
96-well elution plate (Waters, Milford, USA) was performed on the samples prior to LC-MS analysis. This was performed by sequential washing
with 1 mL each of water and water-methanol (95/5; v/v) followed by two elutions with 1 mL methanol. The elutes were dried employing the 96-
well Micro-DS96 evaporator (Porvair Sciences Ltd., Shepperton, UK) at 37°C and reconstituted in 100 µL of 10% acetonitrile containing 0.1%
formic acid for LC-MS analysis.
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Enzyme activity was monitored through CYP-specific metabolite production. Relative activity (100%) was defined in terms of metabolite
production in the absence of inhibitor. The nonlinear-regression was generated by profiling the extract concentration against observed enzyme
activity. The kinetic parameters were determined from the generated plot using the SigmaPlot® Enzyme Kinetic software. For each regression,
the R2 > 0.9 and p < 0.05 were taken as the minimum level of significance. The enzyme inhibition parameter (IC50) was calculated based on
kinetic equation for sigmoid curves (Equation 1) where x = concentration; y = relative enzyme activity; and s = slope factor
Results
The inhibitory activity of the crude extracts on the CYP isozymes, profiled against the extract concentration is presented in Figures 1-3.
The IC50 values and their estimated extrapolative significance are presented in Table 3. Extracts of Bowiea volubilis inhibited the metabolic
activity of CYP1A2 and CYP3A4 with IC50 values of 92.3 ± 5.5 g/mL and 8.1 ± 0.6 g/mL respectively (Figure 1). No significant effect was
observed on the activity of CYP2C9 and CYP2C19. Similarly, Spirostachys africana showed inhibitory activity against CYP1A2 and 3A4 with
respective IC50 values of 14.3 ± 0.6 g/mL and 47.4 ± 2.4 g/mL (Figure 2). Tulbaghia violacea only demonstrated a relatively mild inhibitory
activity against CYP1A2 (767.4 ± 10.8 g/mL) and CYP2C9 (921 ± 15.3 g/mL) (Figure 3).
Table 1: Probe substrates, microsomal protein concentrations and incubation time
Enzyme Probe substrate Microsome
concentration
(mg protein/mL)
Probe substrate
concen-tration
(µM)
Literature
Km value
(µM)
CYP-specific
inhibitors
CYP1A2 Phenacetin 0.2 10 9.01, 142, 313,
544
Furafylline
CYP2C9 Diclofenac 0.1 5 3.45, 9.06 Sulfaphenazole
CYP2C19 S-mephenytoin 0.5 30 517, 428, 319 Ticlopidine
CYP3A4/5 Testosterone 0.2 30 50-6010, 5111 Ketoconazole
1Tassaneeyakul et al, 1993; 2Brosen et al., 1993; 3Venkatakrishnan et al., 1998a; 4Rodrigues et al., 1998; 5Transon
et al., 1996; 6Bort et al., 1999; 7Coller et al., 1999; 8Venkatakrishnan et al., 1998b; 9Schmider et al., 1996; 10Draper
et al., 1998; 11Kenworthy et al., 2001
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Figure 1: The influence of the crude extracts of Bowiea volubilis on the metabolic activity of A) CYP1A2, B) CYP2C9, C) CYP2C19 and D)
CYP3A4.
IC50 = 92.3 ± 5.5 g/mL No inhibition observed
IC50 = >1000 g/mL
IC50 = 8.1 ± 0.6 g/mL
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Figure 2: The influence of the crude extracts of Spirostachys africana on the metabolic activity of A) CYP1A2, B) CYP2C9, C) CYP2C19 and
D) CYP3A4.
Table 3: Summary of the inhibitory effects of the medicinal herbs on CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Bowiea volubilis Spirostachys africana Tulbaghia violacea
CYP1A2 [IC50 (µg/mL)] 92.3 ± 5.5 14.3 ± 0.6 767.4 ± 10.8
CYP2C9 [IC50 (µg/mL)] - - 921 ± 15.3
CYP2C19 [IC50 (µg/mL)] >1000 - >1000
CYP3A4 [IC50 (µg/mL)] 8.1 ± 0.6 47.4 ± 2.4 >1000
Extraction yielda (%w/w) 15.6 18.1 16.4
Usual (single) dose (mg)b 10,000 10,000 10,000
Estimated extract per dose (mg)c 1560 1810 1640
Putative GIT conc (g/mL)d 6240 7240 6560
a This is laboratory extraction yield using water
b Usual traditional doses vary widely. On the average, 10-50g of the herbal materials is extracted and the decoctions are
taken over time (3-6 times). Thus each consumption represent an extract of >1g
c This is based on the assumption that similar yield is obtained in the traditional process of decoction or extraction
d The estimation of putative GIT concentration is based on the average volume of GIT fluid (250mL)
(-) indicates the absence of inhibition
IC50 = 14.3 ± 0.6 g/mL No inhibition observed
No major inhibition observed IC50 = 47.4 ± 2.4 g/mL
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Figure 3: The influence of the crude extracts of Tulbaghia violacea on the metabolic activity of A) CYP1A2, B) CYP2C9, C) CYP2C19 and D)
CYP3A4.
Discussion
This study has demonstrated the potential of Bowiea volubilis, Spirostachys africana and Tulbaghia violacea, three of the most
commonly consumed medicinal herbs in South Africa, to inhibit metabolic activity of CYP1A2, CYP2C9, CYP2C19 and CYP3A4. A summary
of the results presented in Table 3 suggests a high likelihood of in vivo inhibitory effects. No study has reported the influence of any of the herbs
on metabolic enzymes.
In traditional practice, all selected herbs are taken as aqueous extracts, as gathered from the THPs. Thus, an aqueous extraction was
used in this study to reflect the consumption and what consumers are exposed to during medical use of the plants. While single-dose decoctions
are common as dosage regimes, higher amounts of herbal products are often decocted and taken several days in the course of treatment. Thus, it is
difficult to determine uniform doses of traditional medications. The estimates provided however, were determined based on the information
gathered from the THPs and the determined weight of sampled doses.
Based on the approximated intestinal fluid volume of 250 mL and the laboratory extraction yields, putative achievable concentrations of
the herbal extracts in the GIT were determined as shown in Table 3. The extent and efficiency of extraction of the herbs in the intestine may vary
from laboratory extraction due to several factors: intestinal fluid composition, GIT transit time, disease state and dosage form. While the IC50
values vary, a cursory look at Table 3 shows that the putative and achievable GIT concentration of the herbal extract is 20-500 times the observed
IC50 values. Such high concentrations in the GIT portend a high potential to inhibit the pre-systemic CYP-dependent metabolism of drugs, thus
altering the expected pharmacokinetic profiles. This is important because of the rich expression of CYP in the intestines (Ufer et al., 2008).
Each of the herbs investigated in this study inhibited at least one metabolic enzyme. Information on the systemic bio-availability of the
herbal extracts is not available. However, the long history of the folkloric use of these medicinal herbs for systemic disorders, and the high
putative GIT concentrations of the extracts, are indications of their potentially high systemic bioavailability. Systemic availability of phyto-
constituents increases the potential for enzyme inhibition and HDI. The traditional indications of the medicinal herbs cut across a wide variety of
disease conditions. This makes them candidates for potential HDI of variety of prescription drugs.
There are a few limitations to the current study. The known variation of the phytochemical composition of medicinal plants due to place
and time of harvest limits the generalization of the findings of this study (Ozkan et al., 2010). Although, the process of sourcing and extraction of
the herbs was considered representative of the popular practice in South Africa, it should be noted that several herbal products are now available
in capsules and other dosage forms and may be obtained commercially from non-THPS. The findings in this study are based on crude extracts
only. The determination of the exact compounds exerting inhibitory activity on the drug metabolism was beyond the scope of this study.
IC50 = 767.4 ± 10.8 g/mL IC50 = 921 ± 15.3 g/mL
IC50 = >1000 g/mL
IC50 = >1000 g/mL
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Table 2: Summary of the LC/MS analytical conditions for the quantitative determination of the metabolites
Conditions Acetaminophen 4’-hydroxy-diclofenac 4'-hydroxy-mephenytoin 6-hydroxy-testosterone
Mobile phase (plus 0.1% formic
acid)
A: Water
B: Acetonitrile
Gradient of mobile phase: Time
range
A
(%)
B
(%)
0.0-1.0 65 35
1.0-1.1 1.0 99
1.1-5.5 1.0 99
5.5-5.6 65 35
5.6-10 65 35
Time
range
A
(%)
B
(%)
0.0-1.0 50 50
1.0-2.0 5 95
2.0-8.0 5 95
8.0-8.1 50 50
8.1-11. 50 50
Time
range
A
(%)
B
(%)
0.0 - 0.5 85 15
0.5 - 2.0 55 15
2.0 - 4.0 5 95
4.0 - 4.2 5 95
4.2 - 8.0 85 15
8.0 85 15
Isocratic 70% A and 30% B
Injection volume (L) 2.5 2
Flow speed (L / min) 300 60
Column type Luna Phenyl-Hexyl 3 µm, inner dimensions 50 x 1 mm (Phenomenex, Torrance, USA)
Column temperature 40°C 30°C
Nebulizing temperature 375°C
Mode Positive Negative Positive
Quantifier transition (m/z) 180.2 / 110.1 293.88/249.00 169.4/102.3 289.2/96.8
Qualifier transition(s) (m/z) 180.2 / 138.1 No qualifier with a suitable intensity
Dwell time (msec) 400 300 200
Retention time (min) 3.35 6.65 6.65 3.2
Total run time (min) 10 11 8 5
Lower limit of detection 0.1 M 0.1 M 0.1 M 0.05 M
Internal standard Thiacetazone (Retention time- 3.4 min; Quantifier transitions - 293.88/249.00)
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The use of HLM is well accepted to assess the potential of new chemical entities and drug candidates for drug interactions. This
technology has also been widely used to assess the HDI potentials. The results from such studies provide an indication for clinically significant
interactions. Results from in vitro metabolic studies have been extrapolated for in vivo correlation with some degree of predictability (Umehara
and Camenisch, 2012). However, there are still challenges in quantitative extrapolation of in vitro data to humans. At best, the results from in
vitro assessment of HDI can be considered qualitative only.
Conclusion
Extracts of Bowiea volubilis inhibited the metabolic activity of CYP1A2 and CYP3A4; Spirostachys africana showed inhibitory
activity against CYP1A2 and CYP3A4; while the extracts of Tulbaghia violacea inhibited the metabolic activity of CYP1A2 and CYP2C9. The
results suggest the potential for HDI between the herbs and the substrates of the affected enzymes, if sufficient in vivo concentration is achieved.
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